Glutamate release Dopamine release TRPV 1 vanilloid receptor Cannabinoid Striatum a b s t r a c t Endogenous analogues of capsaicin, N-acyldopamines, were previously identified from striatal extracts, but the putative presynaptic role of their receptor, the TRPV 1 R (formerly: vanilloid or capsaicin receptor) in the caudate-putamen is unclear. We found that the endogenous TRPV 1 R agonists, Narachidonoyldopamine (NADA) and oleoyldopamine (OLDA) with EC 50 values in the nanomolar range, as well as the synthetic TRPV 1 R activator 2-aminoethoxydiphenylborane (2APB), and palmytoyldopamine (PALDA, another endogenous N-acyldopamine inactive at the TRPV 1 R), but not capsaicin or other endogenous and synthetic cannabinoids, triggered a rapid Ca 2þ entry with the concomitant stimulation of glutamate and dopamine release. These effects persisted in the TRPV 1 R null-mutant mice, and were insensitive to antagonists of common ionotropic receptors, to several TRPV 1 R antagonists and to the absence of K þ . Furthermore, these N-acyldopamine receptors in glutamatergic and dopaminergic terminals are different based on their different sensitivity to anandamide, capsazepine and Gd 3þ at nanomolar concentrations. Altogether, novel ion channels instead of the TRPV 1 R mediate the presynaptic action of N-acyldopamines in the striatum of adult rodents.
Introduction
The transient receptor potential vanilloid type-1 receptor (TRPV 1 R) is a non-selective Ca 2þ and Na þ channel activated by heat, protons, inflammatory agents, endovanilloids and the pungent substance, capsaicin of chilli pepper, and is involved in peripheral and central pain transmission and procession (Caterina et al., 1997; Avelino and Cruz, 2006; Nagy et al., 2008) . The so-called endovanilloids are diverse lipidomics (mostly arachidonate-derivatives) (Starowicz et al., 2007) , and among them, perhaps anandamide (arachidonoylethanolamine, AEA, Fig. 1C ) is the most studied as it also activates the inhibitory metabotropic type-1 cannabinoid receptor (CB 1 R) (Devane et al., 1992; Lovinger, 2008) . N-arachidonoyldopamine (NADA) is another endogenous ligand capable of activating both the CB 1 R and the TRPV 1 R, and belongs to the recently described family of N-acyldopamines (Starowicz et al., 2007) . Several similar fatty acid dopamide conjugates have been identified in striatal extracts, among which NADA and N-oleoyldopamine (OLDA) (Fig. 1C) are as efficacious and potent as capsaicin at the TRPV 1 R (Huang et al., 2002; Chu et al., 2003) . However, the observation that palmytoyldopamine (PALDA; Fig. 1C ) lacks agonist activity at the TRPV 1 R (Chu et al., 2003) prompts the hypothesis that N-acyldopamines may have additional targets. In the brain, TRPV 1 Rs display higher density in the cortex, the hippocampus, the preoptic area, the medial basal hypothalamus, the locus coeruleus and the basal ganglia (Mezey et al., 2000; Sanchez et al., 2001; Szabó et al., 2002; Roberts et al., 2004; Tó th et al., 2005; Cristino et al., 2006) . Marinelli et al. (2003 Marinelli et al. ( , 2005 Marinelli et al. ( , 2007 found that TRPV 1 R activation can directly stimulate dopamine release or glutamatergic transmission in the substantia nigra pars compacta, the ventral tegmental area and the nucleus accumbens of the rat. In the striatum, presynaptic TRPV 1 Rs desensitize rapidly, but the activation of protein kinase C (PKC) unmasks TRPV 1 Rmediated presynaptic facilitatory actions (Musella et al., 2009) . Thus, in the absence of PKC activation, predominantly postsynaptic TRPV 1 R activation can be detected which down-regulates the post-synaptic release of 2-arachidonoylglycerol (2-AG) (Maccarrone et al., 2008) . Importantly, 2-AG (Fig. 1C ) is another major CB 1 R agonist functioning as a retrograde messenger in the synapse (Stella et al., 1997; Lovinger, 2008) ; hence post-synaptic TRPV 1 R activation may set free glutamatergic terminals from CB 1 Rmediated inhibitory control.
Based on these observations, one would expect that TRPV 1 R activation causes hyperkinesia either by decreasing 2-AG release locally in the striatum or by increasing glutamate and/or dopamine release via the activation of the striatal afferents. Surprisingly, the opposite is the case: TRPV 1 R agonists, either systemically or locally administered, induce hypokinesia and decrease nigrostriatal activity and striatal DOPAC content, inasmuch as TRPV 1 R antagonists induce hyperactivity (Di Marzo et al., 2001; de Lago et al., 2004; Tzavara et al., 2006) . Thus, these controversial data invite further studies since the role of the endovanilloid system in neuromodulation and in neurological and psychiatric disorders has been emerging.
In this present study, we aimed at analyzing the presynaptic role of capsaicin, anandamide, NADA and OLDA in a relevant brain area, namely, the striatum. We used nicotine as a positive control, and PALDA as a negative one. Our goal was to monitor the dynamics of intrasynaptosomal Ca 2þ level changes upon administration of vanilloid ligands, together with their potency and efficacy to induce glutamate and dopamine release.
Methods

Preparation of synaptosomes
All studies were conducted in accordance with the principles and procedures outlined in the EU guidelines and were approved by the local Animal Care Committee of the Institute. All efforts were made to reduce the number of animals used and to minimize their suffering. Therefore all rats (male Wistar rats, 140-160 g, 6-8-week old, vendor: Charles-River, Barcelona, Spain) and wild-type mice (C57bl/ 6, 10-12-week old, vendor: Charles-River, Barcelona, Spain) and genotyped TRPV 1 R null-mutant mice (C57bl/6, 10-12-week old, vendor: The Jackson Laboratory) were anesthetized with halothane before being decapitated. Striata from two rats (fluorimetry) or one rat or one mouse ( 45 Ca 2þ uptake assay and [
C]glutamate and [
3 H]DA release assay) were quickly removed into ice-cold sucrose solution (0.32 M, containing 5 mM HEPES, pH 7.4) and were homogenized instantly with a Teflon homogenizer, and centrifuged at 5000 g for 4 min. The supernatant was centrifuged at 13,000 g for 10 min. The mitochodrium-free fraction of the pellet was collected and washed at 13,000 g for 2 min in 45% Percoll solution at 4 C, then decanted and stored sealed on ice.
Fluorimetric assay
Experiments were performed as described by us earlier (Kö falvi et al., 2007): synaptosomal pellets (w1 mg protein) were preincubated with Fura2/AM (5 mM) for 15 min at 25 C in the incubation solution of the following composition: NaCl (132 mM), KCl (1 mM), MgCl 2 (1 mM), CaCl 2 (0.1 mM), H 3 PO 4 (1.2 mM), glucose (10 mM), HEPES (10 mM), pH 7.4. Then the pellet was centrifuged at 13,000 g, (Grynkiewicz et al., 1985) .
Calculation
In each experiment, vehicle controls and treatments were performed in duplicate. The average of the daily vehicle controls was subtracted from the average of the treatments. Then, a forecast line was fitted to the first 45 data points (representing the 90 s pre-treatment period) with linear regression. Drug effects were calculated as the change in [Ca 2þ ] i (nM)/min, compared to the forecast line with the area under the curve method. ] i , based on the equation of Grynkiewicz et al. (1985) . The emission of WIN55212-2 and 2-AG was determined by the use of a Spex spectrofluorometer. Cuvettes were filled with 2 ml of milliQ water to determine the emission of 510 nm light at 340 and 380 nm excitation, and subsequently vehicle (ethanol) or the tested compound (with the same amount of vehicle) was applied, and results from six independent observations were averaged. As a consequence that 2-AG significantly absorbs more light at 340 than at 380 nm it decreases the Em 340 /Em 380 ratio significantly and concomitantly, falsely diminishes [Ca 2þ ] i readings.
Effect of drugs on absorbance and emission
45 Ca 2þ uptake assay
Experiments were carried out in the same manner (timing, conditions, and assay solutions) as in the fluorimetric assay. Synaptosomal aliquots of 50 ml (w1-2 mg) were diluted to 600 ml in the assay solution and kept at 37 C for 5 min. Then 400 ml of pre-warmed assay solution containing 45 Ca 2þ (isotope purchased from PerkinElmer) and the vehicle or drug tested was added to the synaptosomes. The final concentration of the isotope was 0.5 mCi/ml. Sixty second later, 1 ml of ice-cold Ca 2þ -free assay solution containing 10 mM EGTA/30 mM TRIS (pH 9.6) was added to stop reactions and the samples were vacuum-filtered immediately in GF/B filters. The H]dopamine (GE Healthcare) were added to the synaptosomes for 10 min. All solutions contained the glutamate decarboxylase inhibitor aminooxyacetic acid (100 mM) and the MAO-B inhibitor pargyline (10 mM). A 16-microvolume chamber perfusion setup was filled with the preloaded synaptosomes which were trapped by layers of Whatman GF/C filters and superfused continuously at a rate of 0.7 ml/min until the end of the experiment with oxygenated Krebs' solution at 37 C. Upon termination of the 15-min washout, 2-min samples were collected for liquid scintillation assay, and the filters were also harvested to obtain the total radioactivity content. In each experiment, treatments were applied in quadruplicate (i.e. 4 chambers served as control averaged as n ¼ 1 and three other treatments were applied in the rest of the 3-times 4 chambers). All drugs were perfused from the 6th min of sample collection for 3 min. High K þ was applied as isomolar substitution of Na þ by K þ in the buffer. The proportion of dopamine and glutamate in the released radioactivity was confirmed to be >95%, as previously reported (Kö 
Data treatment
All data represent mean AE SEM of n ! 5 observations. After subtracting the respective control value from the effect of treatment, statistical significance was calculated by column statistics (difference from the hypothetical value of zero if the question was whether a treatment has had any effect or not), Student's t-test or ANOVA followed by Bonferroni's test. A p < 0.05 was accepted as significant difference.
Drugs
HEPES, WIN55212-2, sucrose, aminooxyacetic acid, nicotine, sulpiride, and ionomycin were obtained from Sigma, Saint Louis, Missouri, USA. Arachidonoylethanolamide (anandamide, AEA), 2-arachidonoylglycerol (2-AG), SB366791, 2-aminoethoxydiphenylborane (2APB), Ruthenium Red, iodoresiniferatoxin (IRTX), AM251, (þ)-tubocurarine chloride, and pyridoxalphosphate-6-azophenyl-2 0 ,4 0 -disulfonic acid tetrasodium salt (PPADS) were obtained from Tocris Bioscience, UK. N-arachidonoyldopamine (NADA), N-oleoyldopamine (OLDA), palmytoyldopamine (PALDA), nifedipine, D-(À)-2-amino-5-phosphonopentanoic acid (D-AP5), CNQX, and (À)-bicuculline methobromide were purchased from Ascent Scientific, UK. Fura2/ AM was purchased from Alfagene (Lisbon, Portugal). Non-water soluble substances were dissolved or reconstituted in ethanol at different concentrations and aliquoted and stored at À20 C. Stocks of cannabinoid and vanilloid agonists to be tested were always diluted by 1000 times to have always the same concentration of vehicle in the buffer.
Results
Validation of the fluorimetric assay
In rat striatal nerve terminals, the concentration of intracellular free Ca 2þ ([Ca 2þ ] i ) was 101.9 AE 8.5 nM (n ¼ 76) in the beginning of the recording in accordance with previous studies both in whole cells and in nerve terminals (Lauckner et al., 2005; Kö falvi et al., 2007) . To test the functionality of presynaptic ligand-gated ion channels in our experimental model we used nicotine, the classical agonist of choice in the striatum (Zhou et al., 2002) . Nicotine (1-100 mM) induced a rapidly developing and desensitizing Ca 2þ transient in a concentration-dependent fashion followed by a sustained but lower elevation of [Ca 2þ ] i at higher nicotine concentrations (Fig. 1A,D ] i values with direct measurement; and C) to confirm our calculations on the lack of effect of 2-AG and WIN55212-2. Both NADA (10 mM) and OLDA (10 mM) induced significant Ca 2þ uptake with values similar to those found with the fluorimetric assay (Fig. 2) . Interestingly, PALDA (10 mM), which is inactive at the TRPV 1 R, also induced a Ca 2þ uptake of similar size. 2APB (100 mM), which is a sensitizer ( 100 mM) and an activator (!100 mM) of the homomeric TRPV 1 R, TRPV 2 R, and TRPV 3 R (Hu et al., 2004) , also induced Ca 2þ uptake twice as large as NADA. Neither the hybrid TRPV 1 R/CB 1 R agonists, anandamide (10 mM) and R-methanandamide (10 mM) nor the CB 1 R agonists, 2-AG (10 mM) and the synthetic WIN55212-2 (1 mM) triggered statistically significant Ca 2þ uptake.
N-acyldopamines trigger the release of dopamine and glutamate
To validate this neurochemical procedure, K þ and nicotine were employed to stimulate transmitter release. Both K þ (10 and 15 mM) and nicotine (100 mM) induced a rapidly developing dopamine and glutamate release which returned to baseline upon washout (Fig. 3A,B) . Total amounts of released dopamine and glutamate upon drug superfusion are displayed in Fig. 4 . K þ triggered the release of glutamate and dopamine to a similar extent, while nicotine mostly affected the release dopamine (yet, its effect on the release of glutamate was also statistically significant) (Fig. 3A,B and Fig. 4A ). Yet, in K þ -free medium, the effect of NADA was unchanged (Fig. 4B ). Somewhat surprisingly, the nicotine-evoked release of dopamine (Fig. 4A ) decreased by 53% (n ¼ 5, p < 0.05) but not that of glutamate (n ¼ 5, p > 0.05) in the absence of K þ .
Inhibitors of TRPV channels, the CB 1 receptor, and common ionotropic receptors fail to modify the NADA-induced release of dopamine and glutamate
Although the ion channels involved in the endovanilloids' action display a mixed TRPV 1 R and non-TRPV 1 R pharmacology neither the selective and potent TRPV 1 R antagonists, iodoresiniferatoxin (IRTX, 1 mM) and SB366791 (1 mM) nor the non-selective TRPV 1 , TRPV 2 , TRPV 3 and TRPV 4 channel blocker Ruthenium Red (10 mM) antagonized the effect of NADA (Fig. 4B) . In contrast to hippocampal nerve terminals (Kö falvi et al., 2007) Ruthenium Red did not induce transmitter release alone indicating the lack of TASK-3 K þ channels in striatal dopaminergic and glutamatergic terminals (data not shown). The putative role of another class of voltage-gated cation channels, the L-type Ca 2þ channels was investigated with the Ca 2þ channel blocker nifedipine (1 mM) which did not alter the amplitude of NADA's effect (Fig. 4B) . As NADA being a dual CB 1 R/TRPV 1 R agonist, we investigated tested NADA (10 mM) under CB 1 R blockade by the CB 1 R-selective antagonist, AM251 (1 mM). AM251 did not significantly change the amplitude of NADA's effect on the release of dopamine and caused a non-significant (p ¼ 0.106) facilitation on the release of glutamate (n ¼ 6, Fig. 4B ). Ionotropic glutamate receptor antagonists, CNQX (50 mM) and AP-5 (10 mM); the nicotinic and 5-HT 3 receptor antagonist, tubocurarine (10 mM); the GABA A receptor antagonist, bicuculline (10 mM); and the P2X receptor antagonist, PPADS (10 mM) also failed to modify the action of NADA (Fig. 4C ).
3.6. Anandamide, capsazepine and Gd 3þ reveal different
NADA receptors
Interestingly, anandamide (10 mM) triggered a statistically significant (though very little) release of dopamine (Fig. 3C, Fig. 5B ) but not that of glutamate (Fig. 3D) . Furthermore, capsazepine, which is a low-potency TRPV 1 R antagonist thought to be selective over the other TRP channels, attenuated the effect of NADA on the release of dopamine by 59% (n ¼ 6, p < 0.05 by ANOVA of repeated measures test) but did not modify the effect of NADA on the release of glutamate (Fig. 4B) . Recent reports showed that TRPV channels can be inhibited by the trivalent cation Gd 3þ at mid-micromolar concentrations (as for the TRPV 1 R, above 100 mM) (Tousova et al., 2005; Leffler et al., 2007) . In our study, Gd 3þ fully abolished the effect of NADA, OLDA, PALDA and 2APB at a concentration as low as 3 mM (Fig. 5A,B) . The ultra high potency of Gd 3þ against NADA's effect on the release on dopamine (IC 50 , 745 nM) was even surpassed on the release of glutamate (IC 50 , 153 nM) (Fig. 5A ). Gd 3þ (3 mM) failed to affect the K þ (15 mM)-evoked release of both transmitters (data not shown).
3.7. The effect of NADA, OLDA, PALDA and 2APB persists in the TRPV 1 R null-mutant mice
In the following step, we verified that the effect of the three fatty acid dopamides (all at 10 mM) and of 2APB (100 mM) is present in another species, the wild-type C57bl/6 mice. Additionally, we found that all four ligands triggered the release of glutamate and dopamine in the TRPV 1 R null-mutant (''knockout'') mice, and the size of effects was not statistically different (p > 0.05, n ¼ 5) from that in the wild-type (Fig. 6 ).
Discussion
N-acyldopamines, NADA and OLDA, have been so far considered as selective endogenous agonists for the TRPV 1 R (formerly: VR1 vanilloid or capsaicin receptor) among ligand-gated ion channels (Huang et al., 2002; Chu et al., 2003) . We report now that N-acyldopamines, NADA, OLDA and PALDA, posses new presynaptic targets in the striatum which are linked to rapid Ca 2þ entry and the concomitant release of dopamine and glutamate. The amplitude of effects exceeds that of nicotine and is similar to that of K þ (15 mM) depolarization, arguing for the significance of this novel presynaptic neuromodulation mechanism in the striatum.
The suitability of our experimental models
Importantly, we have chosen to measure dopamine and glutamate release as they represent the major input terminals of the complex of the caudate-putamen nuclei. Synaptosomal preparations are the golden standard to test presynaptic neuromodulation devoid of tonic effects and polysynaptic/glial influences (Raiteri and Raiteri, 2000) . To test presynaptic ligand-gated ion channel functionality in our experimental models, we utilized nicotine, the classical agonist of choice. Nicotine typically increases striatal dopamine levels and consequently, stimulates locomotor activity in rodents (Zhou et al., 2002) . The two classes of nACh receptors mediating nicotine's effect in striatal dopaminergic terminals are formed mostly of a 4 , a 5 , a 6 , b 2 , and b 3 subunits (Salminen et al., 2004) . In our study, nicotine induced rapid Ca 2þ transients in a concentration-dependent fashion followed by a sustained but lower elevation of [Ca 2þ ] i at higher nicotine concentrations. This latter phase may be mediated by a slowly inactivating second nAChR class. Or else, the 53% decrease in nicotine's effect on the release of dopamine in K þ -free solution suggests that nAChRs inhibited a slowly inactivating K þ conductance, resulting in membrane depolarization (Hamon et al., 1997) . Altogether, our neurochemical tools are able to directly demonstrate Ca 2þ transients and the consequent release of neurotransmitters upon activation of presynaptic ligand-gated ion channels.
N-acyldopamines activate striatal input terminals
NADA and OLDA, the two endogenous agonists of the TRPV 1 R, being equipotent and equally efficacious to capsaicin, and PALDA, which does not activate the TRPV 1 R (Huang et al., 2002; Chu et al., 2003) per se triggered Ca 2þ entry and the release of dopamine and glutamate. Apart from these N-acyldopamines, a non-selective enhancer/activator of the TRPV 1 , TRPV 2 and TRPV 3 receptors, 2APB (Hu et al., 2004) , also triggered Ca 2þ entry and consequently, the release of both dopamine and glutamate. Somewhat amplitudes for NADA, OLDA and 2APB are 2-2.5-times greater than in the rat, whereas the effect of PALDA is the same (w4% release of the total releasable pool), indicating slight species differences.
contradictorily, 2APB and PALDA triggered twice as large Ca 2þ uptake but only half as much transmitter release as NADA and OLDA did. Yet, this discrepancy can be easily resolved knowing that 2APB evokes large GABA release (shown so far only in the hippocampus; Kö falvi et al. , 2006) . As the striatum is the largest GABAergic nucleus in the brain with a robust density of GABAergic axon terminals, the effect of PALDA and 2APB on Ca 2þ entry may involve GABAergic nerve terminals too, whereas the effect of OLDA and NADA may be more restricted to the input terminals.
4.3. N-acyldopamines depolarized striatal nerve terminals via targets other than the TRPV 1 R Notably, different concentrations of the general TRPV 1 R agonists, capsaicin, anandamide and R-methanandamide did not trigger significant [Ca 2þ ] i rise, Ca 2þ uptake and evoked transmitter release. This is in agreement with recent findings indicating that PKC activation is a pre-requisite to prevent rapid TRPV 1 R desensitization in striatal glutamatergic terminals (Musella et al., 2009; Maccarrone et al., 2008) , which is probably also true for dopaminergic terminals in our experimental models. Yet, anandamide had a small but significant stimulatory effect on the release of dopamine. This indicates that the close to significant effect of anandamide in the Ca 2þ assay might have resulted from the stimulation of a small Ca 2þ entry in a subpopulation of the total nerve terminal population. Altogether, 1) the lack of effect of capsaicin, anandamide and R-methanandamide; 2) the agonist activity of PALDA; 3) the lack of antagonism by iodoresiniferatoxin, SB3366791, and Ruthenium Red; and 4) the persisting effects in the TRPV 1 R knockout mice all suggest that N-acyldopamines posses additional, previously unidentified targets to control striatal input terminals.
Possible targets of N-acyldopamines
The targets of N-acyldopamines may be cation channels in the cell membrane. Concluding from the experiments without K þ in the buffer and with nifedipine, these N-acyldopamine receptors are not sensitive to membrane potential and/or are not linked to activation of voltage-gated Ca 2þ channels. Furthermore, they are highly sensitive to the channel blocker Gd 3þ whereas the K þ -evoked release of the two transmitters was not.
Although 2APB is a sensitizer and activator of the TRPV 2 R and the TRPV 3 R (Hu et al., 2004) , these novel N-acyldopamine receptors do not seem to be identical with any known member of the TRPV family: 1) we found that Gd 3þ was a two-three orders of magnitude more potent antagonist than at the TRPV 1 R and the TRPV 2 R channels (Tousova et al., 2005; Leffler et al., 2007) ; and 2) Ruthenium Red, the general inhibitor of the TRPV 1-6 channels, failed to prevent the action of NADA. Additionally, anandamide and 2-AG are activators of the TRPV 4 R, and the lack of their putative effect in the Ca 2þ level assays do not indicate the involvement of TRPV 4 Rs in the observed effect of N-acyldopamines (Nilius et al., 2004) . TRPA 1 receptors can be activated by WIN55212-2 (Jeske et al., 2006) which did not affect Ca 2þ levels in our study. TRPC 6 and TRPM 8 receptors are blocked by 2APB, therefore these channels were also unlikely involved in the effect of N-acyldopamines (Hu et al., 2004) .
Antagonists of other common ion channels such as ionotropic glutamate receptors, GABA A receptors, 5-HT 3 serotonin and nicotinic receptors as well as P2X ATP receptors failed to prevent the effect of NADA. We can also exclude the possible involvement of metabotropic cannabinoid receptors linked to Ca 2þ rise in neurons, namely, the CB 1 R and the GPR55 (Lauckner et al., 2005; Pertwee, 2007) because of the rapid kinetics of Ca 2þ entry and the lack of effect of WIN55212-2 and 2-AG. The lack of functional CB 1 Rs in striatal dopaminergic terminals (Kö falvi et al., 2005; Uchigashima et al., 2007) further argues against the involvement of CB 1 Rs. Finally, we can exclude the involvement of (TASK-like) K þ channel blockade as a depolarizing mechanism. We have shown previously that TASK-3 K þ channels control hippocampal nerve terminal membrane potential. TASK-1 and TASK-3 channels can be blocked either by anandamide and WIN55212-2 (Maingret et al., 2001) or by Ruthenium Red (Czirjá k and Enyedi, 2003) . As in the striatal nerve terminals neither anandamide nor Ruthenium Red nor WIN55212-2 induced depolarization, and most importantly, the effect of NADA persists in the absence of K þ , we can exclude the involvement of TASK-1 and 3 channels.
Curiously, the TRPV 1 R antagonist capsazepine significantly inhibited the action of NADA on the release of dopamine. This should account for the partial inhibition of the NADA-induced [Ca 2þ ] i rise. Several present-time cation channels developed from one common ancestor, therefore there is a relatively large structural and/or sequence similarity among many ligand-and voltagegated ion channels bringing about a substantial cross-reaction among their ''selective'' ligands (Kö falvi, 2008) . Capsazepine has been reported to block nAChRs (Liu and Simon, 1997) , HCN1 channels (Ray et al., 2003; Gill et al., 2004) , and voltage-gated Ca 2þ channels (Docherty et al., 1997) . Hence, it is not difficult to imagine that if capsazepine competitively antagonizes the effect of NADA at the TRPV 1 R it can do so at another related ion channel.
Possible consequences of the presynaptic action of N-acyldopamines
Little is known about the recently discovered series of neurotransmitter-fatty acid conjugates such as N-arachidonoyl-glycin, N-arachidonoyl-serotonin or N-arachidonoyldopamine. The latter is shown to be formed and released in dopamine-rich regions (Marinelli et al., 2007) but neither its source nor its enzymatic pathways is delineated. N-acyldopamines may sensitize nerve terminals at subthreshold concentrations with small increases in nerve terminal Ca 2þ levels that could amplify the size of transmitter release upon weak axonal depolarization. Alternatively, they may directly induce transmitter release whereby decreasing the signalto-noise ratio, that is, the reliability of synaptic communication.
They seem capable of inducing Ca 2þ overload which may result in Ca 2þ -mediated cell death. It would be also interesting to know how N-acyldopamine levels change in dopamine deficiency, i.e. in Parkinson's disease and how these changes contribute to the development of syndromes.
